FIELD OF THE INVENTION

[001] The field of the present invention relates to certain curcumin-containing compositions and methods of use thereof, which can be used to modulate miRNA148a levels (and MSK1 production) and thereby ameliorate a variety of health conditions. In addition, the field of the present invention relates to certain curcumin-containing compositions and methods of use thereof, which can be used to modulate miRNA148a levels and thereby lower low-density lipoprotein cholesterol (LDL) levels in a subject.

BACKGROUND OF THE INVENTION

[002] The health benefits of curcumin are known and have been demonstrated by researchers in recent years. However, several challenges continue to exist, with respect to the formulation of curcumin-based pharmaceuticals and dietary supplements. More specifically, the most common source of curcumin, the Indian spice turmeric (a member of Zingiberaceae), does not contain a sufficient amount of curcumin to provide an efficacious dose to a person. In fact, the therapeutic benefits provided by natural curcumin extracts have been relatively modest, inconsistent, and not well understood. Accordingly, there is a continuing need for improved curcumin-based formulations, which address these current challenges.

[003] The present invention, as described further below, addresses many of the foregoing challenges. SUMMARY OF THE INVENTION

[004] According to certain aspects of the present invention, methods for inhibiting the production of MSK-1 (or otherwise reducing the levels of MSK-1 in a plurality of cells) and increasing miRNA148a levels in a plurality of cells are disclosed. In certain embodiments, the methods include providing to the cells an effective amount of a curcumin composition that is at least 5% (w/v) curcumin III or, preferably, at least 30% (w/v) curcumin III or, more preferably, at least 50% (w/v) curcumin III or, even more preferably, at least 70% (w/v) curcumin III, such as at least 90% (w/v) curcumin III. As described further herein, the invention provides that elevated miRNA148a levels, in turn, results in lower MSK1 protein levels (which produces a number of therapeutic benefits). In other embodiments, the invention further encompasses methods of reducing miRNA148a levels in a plurality of cells (if desirable), by providing to the cells an effective amount of curcumin II to reduce miRNA148a levels relative to the levels found in a control cell line. In such embodiments, the methods for reducing miRNA148a levels by providing an effective amount of curcumin II may further be used to reduce and/or manage low-density lipoprotein cholesterol (LDL) levels in a subject.

[005] According to additional aspects of the present invention, methods for inhibiting MSK1 serine ³⁷⁶ phosphorylation in a plurality of cells are disclosed. Such methods generally include providing to the cells an effective amount of a curcumin composition that is at least 5% curcumin III or, preferably, at least 30% (w/v) curcumin III or, more preferably, at least 50% (w/v) curcumin III or, even more preferably, at least 70% (w/v) curcumin III, such as at least 90% (w/v) curcumin III.

[006] According to further aspects of the present invention, methods for ameliorating inflammation in a subject are disclosed. The methods generally include providing to a subject a curcumin III enriched composition that is described herein.

[007] According to yet further aspects of the present invention, methods for ameliorating symptoms in a subject having glucocorticoid-resistant inflammatory disease are disclosed, which include providing to a subject a curcumin III enriched composition that is described herein.

[008] According to still further aspects of the present invention, therapeutic compositions are disclosed that include a curcumin composition consisting of at least 5% curcumin III; optionally, one or more glucocorticoids; and a

pharmaceutically acceptable solvent, filler, or carrier.

[009] In the foregoing aspects of the invention, while the curcumin composition employed may comprise 5% curcumin III, in certain preferred embodiments, the curcumin composition employed may comprise at least 30% curcumin III. Still more preferably, the invention provides that the curcumin composition may comprise at least 50% curcumin III, at least 70% curcumin III or, even more preferably, at least 90% curcumin III.

[0010] According to still further aspects of the present invention, therapeutic compositions are disclosed that include a curcumin composition consisting of at least 15% curcumin II, along with a pharmaceutically acceptable solvent, filler, or carrier.

[0011] The above-mentioned and additional features of the present invention are further illustrated in the Detailed Description contained herein.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

[0012] SEQ ID NO 1 : the nucleic acid sequence of miRNA148a

(UCAGUGCACUACAGAACUUUGU).

BRIEF DESCRIPTION OF THE FIGURES

[0013] FIGURE 1 : MTT assay results demonstrating HEK293 cell survival of approximately 80% for all three curcuminoids (ranging from 20 to 22 pg/mL of the applicable curcuminoid).

[0014] FIGURE 2: MTT assay results demonstrating BV2 cell survival of approximately 80% for all three curcuminoids (ranging from 20 to 22 pg/mL of the applicable curcuminoid).

[0015] FIGURE 3: a bar graph summarizing the effect of curcuminoid III on miRNA148a levels.

[0016] FIGURE 4: measurements of cytoplasmic NFkB-p65 protein levels relative to total protein concentration in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid III, and controls.

[0017] FIGURE 5: measurements of nuclear NFkB-p65 protein levels relative to total protein concentration in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid III, and controls. [0018] FIGURE 6: measurement of cytoplasmic NFkB p65 that is phosphorylated at the serine 276 phosphosite, relative to total protein

concentration in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid III, and controls.

[0019] FIGURE 7: measurement of nuclear NFkB p65 that is phosphorylated at the serine 276 phosphosite, relative to total protein concentration in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid III, and controls.

[0020] FIGURE 8: measurement of cytoplasmic MSK1 protein levels relative to total protein concentration in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid III, and controls.

[0021] FIGURE 9: measurement of nuclear MSK1 protein levels relative to total protein concentration in BV2 cell lines provided with curcumin extract,

curcuminoid I, curcuminoid II, curcuminoid III, and controls.

[0022] FIGURE 10: measurement of cytoplasmic MSK1 that is phosphorylated at the serine 376 phosphosite, relative to total protein concentration in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid

III, and controls.

[0023] FIGURE 11 : measurement of nuclear MSK1 that is phosphorylated at the serine 376 phosphosite, relative to total protein concentration in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid III, and controls. [0024] FIGURE 12: a schematic diagram showing the interaction and influence of curcuminoid III on miRNA148a levels and MSK1.

[0025] FIGURE 13: a bar graph showing that curcumin II down-regulates miRNA148a levels by 17.25% (for the curcumin II only treatment group) and 37.16% (for the curcumin II plus LPS treatment group). Furthermore, the bar graph shows that regular curcumin extract does not influence miRNA148a levels in the same manner.

DETAILED DESCRIPTION OF THE INVENTION

[0026] The following will describe, in detail, several preferred embodiments of the present invention. These embodiments are provided by way of explanation only, and thus, should not unduly restrict the scope of the invention. In fact, those of ordinary skill in the art will appreciate upon reading the present specification and viewing the present drawings that the invention teaches many variations and modifications, and that numerous variations of the invention may be employed, used and made without departing from the scope and spirit of the invention.

[0027] According to certain preferred embodiments, the present invention includes certain curcumin-containing and curcumin-enriched compositions (and methods of using such compositions). More particularly, the present invention includes certain compositions that contain elevated and concentrated levels of curcumin III (relative to the amount of curcumin III found in natural curcumin extract), which can be used to increase miRNA148a (SEQ ID NO:1) levels in a plurality of cells (which, in turn, inhibits MSK1 production), and ameliorate a variety of associated health conditions and/or impart one or more associated health benefits.

[0028] Mitogen- and stress-activated protein kinase 1 (MSK1 ) is a nuclear kinase that plays a significant role in transcription regulation. As described below, the invention provides that curcumin III (and not curcuminoids I and II) can be used to selectively and efficaciously increase miRNA148a levels - which results in the inhibition of cytoplasmic and nuclear MSK1 production, the inhibition of MSK1 serine ³⁷⁶ phosphorylation, and inhibition of the recruitment of MSK1 at inflammatory gene promotors. The curcumin III compositions described herein - and related methods of using such compositions - provide a major step in the transactivation regulation of downstream transcription factors that are key to cell survival and recruitment of inflammatory and immune system events. For example, as demonstrated in the Examples below, the ability of the curcumin III compositions described herein to increase miRNA148a levels, and thereby inhibit MSK1 production (or otherwise significantly reduce MSK1 levels), indicates that such compositions may also (indirectly) be used to modulate NFkB (nuclear factor kappa-light-chain-enhancer of activated B cells) - the aberrant expression and transactivation of which has been linked to cancer, inflammation, and autoimmune diseases. The curcumin III compositions (and related methods) of the present invention provide improved efficacy, reliability, and drug target selectivity, relative to natural curcumin extracts.

[0029] A natural curcumin extract comprises a mixture of curcumin I,

desmethoxycurcumin (curcumin II), and bisdemethoxycurcumin (curcumin III). The term curcumin refers to the principal curcuminoid in the Indian spice turmeric plant (a member of Zingiberaceae). The lUPAC name for the curcumin I molecule is (1 E,6E)-1 ,7-Bis(4-hydroxy-3-methoxyphenyl)-1 ,6-heptadiene-3,5- dione. Although curcumin I may exist in several different tautomeric forms, the enol form is illustrated below:

The lUPAC name for the desmethoxycurcumin (curcumin II) molecule is (1£,6£)- 1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1 ,6-diene-3,5-dione, and has the chemical structure shown below:

The lUPAC name for bis-desmethoxycurcumin (curcumin III) that is used in the compositions and methods of the present invention is (1 E,6E)-1 ,7-bis(4- hydroxyphenyl)hepta-1 ,6-diene-3,5-dione, and has the chemical structure shown below:

[0030] According to certain preferred embodiments, the invention provides that curcumin III may be extracted from turmeric plant rhizome {Curcuma longa) and subsequently concentrated to the desired level. Alternatively, the invention provides that the curcumin III molecule may be chemically synthesized and added to a natural curcumin extract (or the synthesized curcumin III molecule may be used as the sole source of the curcumin III composition described herein). As explained below, the desired concentration may be at least 5%, 30%, 50%, 70%, or 90% (w/v) curcumin III.

[0031] According to certain preferred embodiments of the present invention, methods for increasing miRNA148a levels (and thereby inhibiting the production of MSK1) in a plurality of cells are provided. In such embodiments, the methods include providing to the cells (or administering to a biological system that comprises a plurality of cells) an effective amount of a curcumin composition that is at least 5% curcumin III. According to additional preferred embodiments of the present invention, methods for increasing miRNA148a levels (and thereby inhibiting MSK1 serine ³⁷⁶ phosphorylation) in a plurality of cells are provided. Such methods include providing to the cells (or administering to a biological system that comprises a plurality of cells) an effective amount of a curcumin composition that is at least 5% curcumin III.

[0032] According to further related embodiments of the present invention, methods for ameliorating inflammation in a subject are provided, which generally include providing to a subject an effective amount of a curcumin composition that is at least 5% curcumin III. In these embodiments, the concentration of the curcumin III composition may be enhanced to increase efficacy, such as by providing to the cells (or administering to a biological system that comprises a plurality of cells) a curcumin composition that is at least 5%, 30%, 50%, 70%, or 90% (w/v) curcumin III. The "effective amount" of such curcumin III composition will preferably be sufficient to significantly increase miRNA148a levels, to thereby reduce the amount of MSK1 protein being expressed in the target cells. For example, the "effective amount" of such curcumin III composition will preferably be sufficient to increase miRNA148a levels in the target cells by at least 10% relative to a control (i.e., cells which do not receive the curcumin III composition) or, more preferably, by at least 20% relative to a control.

[0033] According to yet further preferred embodiments of the present invention, methods for ameliorating symptoms in a subject having an adverse medical condition in which MSK1 is implicated are provided, including glucocorticoid- resistant inflammatory diseases and chemotherapy-resistant cancers. In such embodiments, the methods include providing to a subject a curcumin

composition that is at least 5% curcumin III (or, alternatively, at least 30%, 50%, 70%, or 90% (w/v) curcumin III). According to certain related embodiments of the present invention, therapeutic compositions are provided that include a curcumin composition consisting of at least 5% curcumin III; optionally, glucocorticoids; and a pharmaceutically acceptable solvent, filler, or carrier. As used herein, "glucocorticoids" refers to certain steroid hormones that are known to bind to glucocorticoid receptors (RCEs). Non-limiting examples of

glucocorticoids include: Cortisol, cortisone, prednisone, prednisolone,

methylprednisolone, dexamethasone, betamethasone, triamcinolone,

beclometasone, fludrocortisone, deoxycorticosterone, and aldosterone. [0034] In the foregoing embodiments of the invention, while the curcumin composition employed may comprise 5% curcumin III, in certain preferred embodiments, the curcumin composition employed may comprise at least 30% curcumin III. Still more preferably, the invention provides that the curcumin composition may comprise at least 50% curcumin III, at least 70% curcumin III or, even more preferably, at least 90% curcumin III - - depending on the desired potency.

[0035] The invention provides that the concentrated forms of the curcumin III based compositions (and methods of using such compositions) described herein exhibit many benefits - for humans, canines, cats and equine. First, as demonstrated below and described herein, the invention provides that elevated levels of curcumin III will selectively increase miRNA148a levels (which, in turn, inhibits MSK1 production), which thereby produces desirable anti-inflammatory activity. In addition, the invention provides that the compositions and methods described herein may be used for therapeutic nutrition; anti-inflammatory therapy for autoimmune disease and other chronic and acute inflammatory ailments; treatment of pain, swelling and inflammation; nutritional supplementation;

superbug treatments; and antimicrobial, antifungal, antibacterial, and antiviral therapies.

[0036] Still further, according to certain additional embodiments, the present invention encompasses therapeutic compositions (and methods of use thereof) that include a curcumin composition consisting of at least 15% curcumin II, along with a pharmaceutically acceptable solvent, filler, or carrier. In such embodiments, the curcumin ll-enriched compositions can be used to lower miRNA148a levels and thereby lower low-density lipoprotein cholesterol (LDL) levels in a subject. Indeed, as shown in the Example below, curcumin ll-enriched compositions can be used to lower miRNA148a levels (and reduced miRNA148a levels has previously been shown to lower low-density lipoprotein cholesterol (LDL) levels in a subject).

[0037] It is well-established that miRNAs play significant roles in serum lipid management. Several miRNAs have been shown to control proteins that are central to LDL receptor management, including miRNA148a. (See Wagschal, A., et al., Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nature medicine, 2015. 21(11): p. 1290-1297; and Feinberg, .W. and K.J. Moore, MicroRNA regulation of atherosclerosis.

Circulation research, 2016. 118(4): p. 703-720). Previous research has shown that miRNA148a is a negative regulator of low-density lipoprotein receptor (LDLR) expression and activity. (See Goedeke, L., et al., MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nature medicine, 2015. 21(11): p. 1280-1289). Furthermore, inhibition of miRNA148a is a recognized means for ameliorating elevated LDL-C/HDL-C ratios. Indeed, multiple independent studies have recently shown that

miRNA148a inhibition may prove to be an important therapeutic approach for serum LDL downregulation and inhibition of atherosclerosis. (See Rotllan, N., et al., microRNAs in lipoprotein metabolism and cardiometabolic disorders.

Atherosclerosis, 2016. 246: p. 352-360; Goedeke, L., et al., miRNA regulation of LDL-cholesterol metabolism. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 2016. 1861(12): p. 2047-2052; Fernandez-Hernando, C. and L. GOEDEKE, Anti-mir-27b and anti-mir-148a oligonucleotides as

therapeutic tools for treating dyslipidemias and cardiovascular diseases. 2014, WO Patent App. PCT/US2014/042, 196; and U.S. Patent Application Publication 2014/042196, which is hereby incorporated by reference). Accordingly, since the curcumin ll-enriched compositions of the present invention has been shown to selectively reduce miRNA148a levels, it follows that such curcumin ll-enriched compositions may be used to manage and/or reduce low-density lipoprotein cholesterol (LDL) levels in a subject. In such embodiments, the curcumin ll- enriched compositions may consist of, for example, at least 15% (w/v) of curcumin II, or at least 30% (w/v) of curcumin II, or at least 50% (w/v) of curcumin II, or at least 70% (w/v) of curcumin II, or at least 90% (w/v) of curcumin II.

[0038] In certain specific embodiments, the compositions and methods described herein may be used to ameliorate the effects of autoimmune diseases (and other inflammatory conditions), such as rheumatoid arthritis, colitis, nonspecific inflammatory bowel diseases, Crohn's disease, lupus, multiple sclerosis, psoriasis, type-l diabetes, diabetes, myocarditis, thyroiditis, uveitis, systemic lupus erythromatosis, myasthenia and gravis. Furthermore, the compositions and methods described herein may be used to ameliorate the effects of autoimmune syndromes, such as the sources of immune-mediated inflammation (which can promote chronic inflammation, Alzheimer's, asthma, allergies, obesity, chronic fatigue, fibromyelia, premature aging, and general memory impediments). Still further, the compositions and methods may be used for the purpose of performance enhancement; recovery from physical exercise; and to help neutralize lactic acid, oxidation and associated inflammatory responses to workload to improve recovery rate, anabolism, reduce post-workout soreness and associated fatigue (and allow for repeat workout sessions earlier than could otherwise be executed in typical workout and training cycles).

[0039] The invention provides that the compositions described herein may be administered in any desired and effective manner, e.g., as pharmaceutical compositions or nutritional supplements for oral ingestion. More particularly, for example, pharmaceutically acceptable compositions or nutritional supplements of the invention may comprise one or more of the compositions described herein with one or more acceptable carriers. Regardless of the route of administration selected, the compositions may be formulated into acceptable dosage forms by conventional methods known to those of skill in the art. For example, acceptable carriers include, but are not limited to, sugars (e.g., lactose, sucrose, mannitol, and sorbitol), silicon dioxide, starches, cellulose preparations (such as

microcrystalline cellulose), calcium phosphates (e.g., dicalcium phosphate, tricalcium phosphate and calcium hydrogen phosphate), sodium citrate, water, aqueous solutions, alcohols (e.g., ethyl alcohol, propyl alcohol, and benzyl alcohol), polyols (e.g., glycerol, propylene glycol, and polyethylene glycol), organic esters (e.g., ethyl oleate and tryglycerides), biodegradable polymers (e.g., polylactide-polyglycolide, poly(orthoesters), and poly(anhydrides)), elastomeric matrices, liposomes, microspheres, oils (e.g., corn, germ, olive, castor, sesame, cottonseed, and groundnut), cocoa butter, waxes, paraffins, silicones, talc, silicylate, etc.

[0040] Each acceptable carrier used in a pharmaceutical composition or nutritional supplement of the invention must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Carriers suitable for a selected dosage form and intended route of administration are well known in the art, and acceptable carriers for a chosen dosage form and method of administration can be determined using ordinary skill in the art.

[0041] The pharmaceutical compositions and nutritional supplements of the invention may, optionally, contain additional ingredients and/or materials commonly used in pharmaceutical compositions and/or nutritional supplements. Such ingredients and materials include (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone,

hydroxy propyl methyl cellulose, sucrose and acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium starch glycolate, cross- linked sodium carboxy methyl cellulose and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as

quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and glycerol monosterate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, and sodium lauryl sulfate; (10) suspending agents, such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth; (11 ) buffering agents; (12) excipients, such as lactose, milk sugars, polyethylene glycols, animal and vegetable fats, oils, waxes, paraffins, cocoa butter, starches, tragacanth, cellulose derivatives, polyethylene glycol, silicones, bentonites, silicic acid, talc, salicylate, zinc oxide, aluminum hydroxide, calcium silicates, and polyamide powder; (13) inert diluents, such as water or other solvents; (14) preservatives; (15) surface-active agents; (16) dispersing agents; (17) control-release or absorption-delaying agents, such as hydroxypropylmethyl cellulose, other polymer matrices, biodegradable polymers, liposomes, microspheres, aluminum monosterate, gelatin, and waxes; (18) opacifying agents; (19) adjuvants; (20) wetting agents; (21) emulsifying and suspending agents; (22), solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan; (23) propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane; (24) antioxidants; (25) agents which render the formulation isotonic with the blood of the intended recipient, such as sugars and sodium chloride; (26) thickening agents; (27) coating materials, such as lecithin; (28) vitamins and minerals; (29) proteins that carry therapeutic or nutritional benefits, such as whey protein and other milk-derived proteins; and (30) sweetening, flavoring, coloring, perfuming and preservative agents. Each such ingredient or material must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Ingredients and materials suitable for a selected dosage form and intended route of

administration are well known in the art, and acceptable ingredients and materials for a chosen dosage form and method of administration may be determined using ordinary skill in the art.

[0042] Pharmaceutical compositions and nutritional supplements suitable for oral administration may be in the form of capsules, cachets, pills, tablets, powders, granules, a solution or a suspension in an aqueous or non-aqueous liquid, an oil-in-water or water-in-oil liquid emulsion, an elixir or syrup, or a paste. These formulations may be prepared by methods known in the art, e.g., by means of conventional pan-coating, mixing, granulation or lyophilization processes.

[0043] Solid dosage forms for oral administration (capsules, tablets, pills, powders, granules and the like) may be prepared by mixing the active

ingredient(s) with one or more acceptable carriers and, optionally, one or more fillers, extenders, binders, humectants, disintegrating agents, solution retarding agents, absorption accelerators, wetting agents, absorbents, lubricants, and/or coloring agents. Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using a suitable excipient. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using a suitable binder, lubricant, inert diluent, preservative, disintegrant, surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine. The tablets, and other solid dosage forms, such as capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the art. The tablets, and other solid dosage forms, may also be formulated so as to provide slow or controlled release of the active ingredient therein. They may be sterilized by, for example, filtration through a bacteria-retaining filter. These compositions may also optionally contain opacifying agents that release the active ingredient only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. The active ingredient can also be in a microencapsulated form.

[0044] Liquid dosage forms for oral administration include acceptable

emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. The liquid dosage forms may contain suitable inert diluents commonly used in the art. Besides inert diluents, the oral compositions may also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents. Suspensions may contain suspending agents.

EXAMPLES

[0045] The following Examples demonstrate the effects of curcumin III (and curcumin I and II) on miRNA148a levels and cytoplasmic and nuclear MSK1 expression, as well as the effects of curcumins I, II, and III on cytoplasmic and nuclear MSK1 serine phosphorylation. In addition, the Examples below demonstrate the effects of curcumin II on miRNA148a levels.

[0046] Example 1 - MTT Assay. MTT (3-[4, 5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide) assays are routinely used to measure cell viability and survival. In this Example, cytotoxicity of curcuminoids on two cell types - HEK293T and BV2 microglia - was measured. The MTT assay quantifies the formazan production by live cells from the tetrazolium ring cleavage of MTT. Reduction of MTT is directly proportional to metabolic activity and therefore relatable to cell viability and survival. A first MTT assay was performed on HEK293T cells in a 96-well plate requiring 3 x 10 ⁴ cells per well. The MTT assay was also performed using BV2 microglia cells, pursuant to the same protocol (utilizing a 96-well plate requiring 3 x 10 ⁴ cells per well). Dimethyl sulfoxide (DMSO) was used in the test drug (curcuminoid) preparation at 0.2%. The MTT assay was used to measure the health of the cells in culture with various treatment concentrations of various curcumin preparations.

[0047] As shown in Figure 1 (HEK293T cells) and Figure 2 (BV2 microglia), the MTT assay results revealed that the selected cell models are relatively resilient to the curcuminoid drugs at the tested concentrations. Cell survival was shown to begin to decline below 80% survival at a drug (curcuminoid) concentration around 40 pg/ml. Accordingly, a final test concentration of 22 pg/ml was selected and employed in the Examples that follow.

[0048] Example 2 - Effects of Curcuminoids on miRNA148a Levels.

Reverse transcriptase (RT) quantitative PCR (RT qPCR) was performed to measure miRNA 148a levels in cells that were treated with curcumin I, II, or III, or a control. More particularly, six-well plates were seeded with BV2 cells at a concentration of about 1.5 x 10 ⁶ BV2 cells per well. Drug (curcumin I, II, or III) treatment was carried out in the same manner as was executed for the western blot experimentation described in Example 3 below. Ten wells were prepared and, upon confluence, the next day the drug treatment was designed to evaluate basal influence of curcumin extract, curcumin I, curcumin II, curcumin III, as well as each curcumin drug with LPS stimulation. Each well was pre-treated with the drug combinations in accordance to the schematics shown in Figure 3 (and Figure 13). After 30 minutes of incubation with the drug treatment, LPS was used to induce the cells in each well labelled to be induced by LPS.

[0049] RNA was ultimately extracted from the cells to determine the levels of miRNA148a. A Qiagen miRNeasy Mini Kit (Cat. No. 217004) was used to extract total RNA along with miRNA. The miRNA was reverse transcribed to cDNA using a gene-specific RT primer and the miScript II RT Kit by Qiagen (Cat. No.

218161). An miRNA148a primer assay was acquired from Qiagen (Cat. No. 00003556). As shown in Figure 3, miRNA148a regulation by the different curcuminoids is complex and varied. More particularly, the results show that curcumin II inhibits miRNA148a levels (which would ultimately allow for MSK1 translational activity to ensue). In addition, however, the ability of the curcumin ll-enriched composition to inhibit miRNA148a levels will translate into reduced LDL levels in a subject (as discussed above). Conversely, curcumin III increases miRNA148a levels - which, as demonstrated in Example 3 below, is effective to inhibit MSK1 translation / production. This demonstrates the mechanism by which curcumin III is effective to downregulate the production of MSK1 (which is demonstrated below). This relationship is also summarized in Figure 12. To summarize, this Example and the results presented in Figure 3 show that curcumin III (and not curcumin I nor II) significantly increase miRNA148a levels. As demonstrated in Example 3 below, this increase in miRNA148a levels, in turn, inhibits MSK1 protein levels in both separated cytosolic and nuclear fractions. Notably, as mentioned above, the results presented in Figures 3 and 13 further reveal that miRNA148a is reduced by curcumin II - thereby making a curcumin ll-enriched composition useful for reducing LDL levels in a subject. More specifically, as shown in Figure 13, the curcumin II composition was shown to down-regulate miRNA148a levels by 17.25% (for the curcumin II only treatment group) and 37.16% (for the curcumin II plus LPS treatment group). Accordingly, the invention provides that curcumin III may be selectively administered to a plurality of cells to increase miRNA148a levels, whereas curcumin II may be selectively administered to a plurality of cells to reduce miRNA148a levels. More particularly, the curcumin III and curcumin II compositions described herein may be selectively used to modulate miRNA148a levels (up or down), as may be desirable.

[0050] Example 3 - Western Blot Analysis of Cytoplasmic and Nuclear MSK1 Levels. Western blot analysis was performed in multiple varying formats before optimization was achieved. The BV2 microglia cell line was cultured in Dulbecco's Modified Eagle's Medium (DMEM) - complete medium. The complete medium consisted of DMEM, 1 % Ampicillin, and 10% Fetal Bovine Serum (FBS). BV2 microglia cells, at a cell count of approximately 2 x 10 ⁶ , were seeded in each well (6 wells per plate) with 2.0 ml complete medium and cultured overnight in a ThermaForma HepaFilter Series II C02 Incubator at 37° Celsius. Upon establishing confluence, subconfluent cells were washed out and the wells were prepared with drug pre-treatment after overnight incubation.

[0051] The test drugs (curcuminoids) were procured as follows: curcumin I research standard (03926) (ChromaDex Irvine, CA USA) (97.7% purity);

curcumin II research standard (04230) (ChromaDex Irvine, CA USA) (97.3%); curcumin III research standard (B6938) (Sigma-Aldrich St. Louis, Missouri, USA) (97.7% purity); curcumin extract (curcumin I - 77.7%, curcumin II - 16.9%, curcumin III - 0.9%) research standard (03928) (ChromaDex Irvine, CA USA) (95.3% purity); and Lipopolysaccharide (LPS) from E. Coli (L2630) (Sigma- Aldrich St. Louis, Missouri, USA).

[0052] Curcuminoids are not soluble in aqueous medium due to their hydrophobic characteristic. However, curcuminoid extracts are soluble in polar organic solvents, such as DMSO and acetone. In this Example, each

curcuminoid preparation was first dissolved in DMSO. DMSO was used in the drug preparation at 0.2%. The drug/DMSO solution was subsequently dissolved in DMEM to achieve a final drug concentration for each curcuminoid preparation tested - 22.0 Mg/ml curcuminoid. The DMEM/drug solution was used to replace the culture DMEM well medium and incubated for 30 minutes at 37-degrees Celsius in a ThermaForma incubator. At 31 minutes, lipopolysaccharide (LPS at 1.0 μΙ/ml final well concentration) induction of the cells was executed, except for the DMSO-only well to stimulate cell response amidst drug pre-treatment and without drug treatment.

[0053] The plates were then incubated for another 30 minutes after LPS stimulation. Upon removal from incubation, the cell medium was carefully removed and cells were washed, scraped, and collected with phosphate-buffered saline (PBS). Using a ThermoFisher Scientific NE-PER Nuclear and

Cytoplasmic Extraction Kit (obtained from ThermoFisher Scientific Burlington, Ontario Canada), the cells were lysed and the cytoplasmic and nuclear protein fractions were collected and separated with the intention of probing each fraction for subcellular changes in cytoplasmic and nuclear proteins (as described further below).

[0054] Total protein concentration for each fraction was determined using a Bio Rad Protein Assay that is based on the Bradford Assay (dye-binding method). The total protein concentration determination was made prior to test sample preparation for gel electrophoresis execution (described below). The protein concentration colorimetric assay kit was purchased from Bio Rad Laboratories Canada Ltd. (Montreal, Quebec Canada). Each test sample was then prepared for loading and subjected to gel electrophoresis (SDS-PAGE) using a BioRad stain free gel system (Catalog No. 161-0181) and subsequently transferred / blotted to a nitrocellulose membrane (ThermoFisher Scientific Product No.

88018), blocked, and prepared for primary antibody treatment for each target. [0055] The targets analyzed in the Western Blot included NFkB-p65 and its nucleocytoplasmic translocation, as well as kinases (including MSK1) and their covalent modifications upstream of and involved in the regulation of NFkB.

Antibodies against NFkB-p65 (Ab16502) were procured from Abeam Inc.

(Toronto, Ontario, Canada) as a primary antibody to probe for total NFkB-p65 levels in both nuclear and cytoplasmic fractions. Antibodies against

phosphorylated NFkB p65 at serine 276 (sc-101749) were procured from Santa Cruz Biotechnologies Inc. Antibodies against MSK1 total protein (SAB4503597) were procured from Sigma-Aldrich Company (St. Louis, Missouri, USA), and antibodies against phosphorylated MSK1 at serine 376 (SAB4504475) were also procured from Sigma-Aldrich Company. The antibodies were used to probe for both nuclear and cytoplasmic levels of each protein and its modified state - the phosphorylation site which determines its activated (or most active) state.

Secondary antibody conjugated to a horseradish peroxidase (HRPO) enzyme was used to detect the bound primary antibodies. Following incubation, washing, and substrate activation of the HRPO-labeled secondary antibody, the

membrane was scanned using a Bio Rad ChemDoc MP Imaging System (and the detected Western Blot bands were quantified using Image J Software).

[0056] Figure 4 shows the Western Blot measurements of cytoplasmic NFkB- p65 protein levels relative to total protein concentration, in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid III, and controls. Figure 5 shows the Western Blot measurements of nuclear NFkB-p65 protein levels relative to total protein concentration, in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid III, and controls. Figure 6 shows the Western Blot measurements of cytoplasmic NFkB- p65 phosphorylated at serine 276 relative to total protein concentration, in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid III, and controls. Figure 7 shows the Western Blot measurements of nuclear NFkB-p65 that is phosphorylated at serine 276 relative to total protein concentration, in BV2 cell lines provided with curcumin extract, curcuminoid I, curcuminoid II, curcuminoid III, and controls.

[0057] The cytosolic and nuclear NFkB-p65 data (Figures 4 and 5) reveal that nucleotranslocation is not significantly inhibited by curcumin extract, curcumin I, curcumin II, nor curcumin III. As shown in Figures 6 and 7, however, curcumin extract and each of the curcuminoids - I, II, and III - moderately inhibit NFkB-p65 serine ²⁷⁶ phosphorylation to significantly inhibit p65-p50 transactivation, while nucleotranslocation is relatively low in this same context. Indeed, the more robust inhibition of NFkB-p65 serine ²⁷⁶ phosphorylation of the transcription factor's Transactivation Domain II reveals a relevant mechanism by which each of the curcuminoids inhibits p65p50 transactivation and downstream immune and inflammatory activity. These data show that each curcuminoid, including the curcumin extract, comparably inhibits this key site phosphorylation to

downregulate immune system and inflammatory activity. This demonstrates an ability of curcuminoid drugs to treat cells that may feature pathological constitutive p65-p50 nucleotranslocation, which is a common pathological feature of cancer and chronic inflammatory conditions (including autoinflammatory and autoimmune conditions).

[0058] Furthermore, and perhaps even more profound, inhibition of MSK1 protein levels was revealed by Western Blot analysis (Figures 8 and 9). More specifically, it was found that curcumin III - but not curcumin extract, curcumin I or curcumin II - significantly inhibited and downregulated MSK1 protein levels in both the cytoplasm and the nucleus (Figures 8 and 9). The Western Blot analysis summarized in Figures 8 and 9 shows curcumin III selectively inhibits MSK1 expression, while certain other curcuminoids (namely, curcumin II) were only shown to inhibit MSK1 serine 376 phosphorylation (Figures 10 and 11).

[0059] As illustrated in this Example (and in Figures 8 and 9), the inventor discovered that curcumin III displays independent and additional pharmacology leading to MSK1 protein downregulation, and that its influence on MSK1 is likely independent and more selectively focused on MSK1 (and not upstream of the kinase). This Example shows the inhibitory influence that is selectively imparted by isolated and enriched curcumin III compositions (and not the other

curcuminoids). In addition, the Examples show inhibition of MSK1 expression is not conveyed by typical curcumin extracts - likely because the curcumin III levels in such natural extracts is inherently too low to achieve such activity (a typical natural curcumin extract contains low levels of curcumin III, often about 0.2% - 1% curcumin III).

[0060] Example 4 - Curcumin Formulation One. The following describes a non-limiting example, but a preferred embodiment, of a composition that is encompassed by the present invention. More particularly, the composition includes 36 - 40% curcumin I; 9 - 11 % curcumin II; and about 50% curcumin III (e.g., between 45% - 55%). Preferably, such composition is formulated into a capsule that can be administered orally. In such embodiments, the capsule may comprise additional fillers and agents, such as a vegetable capsule

(hydroxypropyl methylcellulose), water, microcrystalline cellulose, magnesium stearate, and silicon dioxide. In such embodiments, a subject may consume 1 - 3 capsules per day (with each capsule including about 1131 mg of the total composition), to achieve the desired effects described herein.

[0061] Example 5 - Curcumin Formulation Two. The following describes another non-limiting example, and another preferred embodiment, of a

composition that is encompassed by the present invention. More particularly, the composition includes 51 - 53% curcumin I; 13 - 14% curcumin II; and about 30% curcumin III (e.g., between 25% - 35%). As with the Example above, such composition is preferably formulated into a capsule that can be administered orally. Likewise, in such embodiments, the capsule may comprise additional fillers and agents, such as a vegetable capsule (hydroxypropyl methylcellulose), water, magnesium stearate, and silicon dioxide. In such embodiments, a subject may consume 1 - 3 capsules per day (with each capsule including about 1131 mg of the total composition), to achieve the desired effects described herein.

[0062] The many aspects and benefits of the invention are apparent from the detailed description, and thus, it is intended for the following claims to cover all such aspects and benefits of the invention which fall within the scope and spirit of the invention. In addition, because numerous modifications and variations will be obvious and readily occur to those skilled in the art, the claims should not be construed to limit the invention to the exact construction and operation illustrated and described herein. Accordingly, all suitable modifications and equivalents should be understood to fall within the scope of the invention as claimed herein.

* * *